Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort
(2013) In Annals of the Rheumatic Diseases 72(8). p.1308-1314- Abstract
- Background The metabolic syndrome (MetS) may contribute to increased cardiovascular risk in systemic lupus erythematosus (SLE). We aimed to examine the association of demographic factors, lupus phenotype and therapy exposure with the presence of MetS. Methods The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis inception cohort enrolled recently diagnosed (<15months) SLE patients from 30 centres across 11 countries from 2000. Clinical, laboratory and therapeutic data were collected according to a standardised protocol. MetS was defined according to the 2009 consensus statement from the International Diabetes Federation. Univariate and backward stepwise multivariate logistic regression were used to assess... (More)
- Background The metabolic syndrome (MetS) may contribute to increased cardiovascular risk in systemic lupus erythematosus (SLE). We aimed to examine the association of demographic factors, lupus phenotype and therapy exposure with the presence of MetS. Methods The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis inception cohort enrolled recently diagnosed (<15months) SLE patients from 30 centres across 11 countries from 2000. Clinical, laboratory and therapeutic data were collected according to a standardised protocol. MetS was defined according to the 2009 consensus statement from the International Diabetes Federation. Univariate and backward stepwise multivariate logistic regression were used to assess the relationship of individual variables with MetS. Results We studied 1686 patients, of whom 1494 (86.6%) had sufficient data to determine their MetS status. The mean (SD) age at enrolment and disease duration was 35.2years (13.4) and 24.1weeks (18.0), respectively. MetS was present at the enrolment visit in 239 (16%). In backward stepwise multivariable regression analysis, higher daily average prednisolone dose (mg) (OR 1.02, 95% CI 1.00 to 1.03), older age (years) (OR 1.04, 95% CI 1.03 to 1.06), Korean (OR 6.33, 95% CI 3.68 to 10.86) and Hispanic (OR 6.2, 95% CI 3.78 to 10.12) ethnicity, current renal disease (OR 1.79, 95% CI 1.14 to 2.80) and immunosuppressant use (OR 1.81, 95% CI 1.18 to 2.78) were associated with MetS. Conclusions Renal lupus, higher corticosteroid doses, Korean and Hispanic ethnicity are associated with MetS in SLE patients. Balancing disease control and minimising corticosteroid exposure should therefore be at the forefront of personalised treatment decisions in SLE patients. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/3973242
- author
- organization
- publishing date
- 2013
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Systemic Lupus Erythematosus, Cardiovascular Disease, Inflammation, Epidemiology
- in
- Annals of the Rheumatic Diseases
- volume
- 72
- issue
- 8
- pages
- 1308 - 1314
- publisher
- BMJ Publishing Group
- external identifiers
-
- wos:000321338400010
- scopus:84880214160
- pmid:22945501
- ISSN
- 1468-2060
- DOI
- 10.1136/annrheumdis-2012-202106
- language
- English
- LU publication?
- yes
- id
- 43aad65a-d575-4e2f-8b70-4ef84403c5da (old id 3973242)
- date added to LUP
- 2016-04-01 13:03:27
- date last changed
- 2022-02-04 02:08:16
@article{43aad65a-d575-4e2f-8b70-4ef84403c5da,
abstract = {{Background The metabolic syndrome (MetS) may contribute to increased cardiovascular risk in systemic lupus erythematosus (SLE). We aimed to examine the association of demographic factors, lupus phenotype and therapy exposure with the presence of MetS. Methods The Systemic Lupus International Collaborating Clinics Registry for Atherosclerosis inception cohort enrolled recently diagnosed (<15months) SLE patients from 30 centres across 11 countries from 2000. Clinical, laboratory and therapeutic data were collected according to a standardised protocol. MetS was defined according to the 2009 consensus statement from the International Diabetes Federation. Univariate and backward stepwise multivariate logistic regression were used to assess the relationship of individual variables with MetS. Results We studied 1686 patients, of whom 1494 (86.6%) had sufficient data to determine their MetS status. The mean (SD) age at enrolment and disease duration was 35.2years (13.4) and 24.1weeks (18.0), respectively. MetS was present at the enrolment visit in 239 (16%). In backward stepwise multivariable regression analysis, higher daily average prednisolone dose (mg) (OR 1.02, 95% CI 1.00 to 1.03), older age (years) (OR 1.04, 95% CI 1.03 to 1.06), Korean (OR 6.33, 95% CI 3.68 to 10.86) and Hispanic (OR 6.2, 95% CI 3.78 to 10.12) ethnicity, current renal disease (OR 1.79, 95% CI 1.14 to 2.80) and immunosuppressant use (OR 1.81, 95% CI 1.18 to 2.78) were associated with MetS. Conclusions Renal lupus, higher corticosteroid doses, Korean and Hispanic ethnicity are associated with MetS in SLE patients. Balancing disease control and minimising corticosteroid exposure should therefore be at the forefront of personalised treatment decisions in SLE patients.}},
author = {{Parker, Ben and Urowitz, Murray B. and Gladman, Dafna D. and Lunt, Mark and Bae, Sang-Cheol and Sanchez-Guerrero, Jorge and Romero-Diaz, Juanita and Gordon, Caroline and Wallace, Daniel J. and Clarke, Ann E. and Bernatsky, Sasha and Ginzler, Ellen M. and Isenberg, David A. and Rahman, Anisur and Merrill, Joan T. and Alarcon, Graciela S. and Fessler, Barri J. and Fortin, Paul R. and Hanly, John G. and Petri, Michelle and Steinsson, Kristjan and Dooley, Mary-Anne and Manzi, Susan and Khamashta, Munther A. and Ramsey-Goldman, Rosalind and Zoma, Asad A. and Sturfelt, Gunnar and Nived, Ola and Aranow, Cynthia and Mackay, Meggan and Ramos-Casals, Manuel and van Vollenhoven, Raymond F. and Kalunian, Kenneth C. and Ruiz-Irastorza, Guillermo and Lim, Sam and Kamen, Diane L. and Peschken, Christine A. and Inanc, Murat and Bruce, Ian N.}},
issn = {{1468-2060}},
keywords = {{Systemic Lupus Erythematosus; Cardiovascular Disease; Inflammation; Epidemiology}},
language = {{eng}},
number = {{8}},
pages = {{1308--1314}},
publisher = {{BMJ Publishing Group}},
series = {{Annals of the Rheumatic Diseases}},
title = {{Clinical associations of the metabolic syndrome in systemic lupus erythematosus: data from an international inception cohort}},
url = {{http://dx.doi.org/10.1136/annrheumdis-2012-202106}},
doi = {{10.1136/annrheumdis-2012-202106}},
volume = {{72}},
year = {{2013}},
}